Chuxiao Shao
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Chuxiao Shao has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Ajith Manayil Parambil
Nanotechnology Centre Centre for Energy and Environmental Technologies VŠB–Technical University of Ostrava Ostrava‐Poruba Czech Republic
1 shared publication - Anuj Kumar Tomar
School of Environmental Sciences, Jawaharlal Nehru University, New Delhi, India
1 shared publication - Chunlai Zeng
Central Laboratory of The Lishui Hospital of Wenzhou Medical University, The First Affiliated Hospital of Lishui University, Lishui People’s Hospital, Lishui, Zhejiang, 323000, People’s Republic of China
1 shared publication - Eepsita Priyadarshini
Department of Biomedical Sciences, School of Biosciences and Technology, Galgotias University, Greater Noida, India
1 shared publication Imran Ibrahim Shaikh
Central Laboratory of The Lishui Hospital of Wenzhou Medical University, The First Affiliated Hospital of Lishui University, Lishui People’s Hospital, Lishui, Zhejiang, 323000, People’s Republic of China
1 shared publicationJianfeng Wang
Central Laboratory of The Lishui Hospital of Wenzhou Medical University, The First Affiliated Hospital of Lishui University, Lishui People’s Hospital, Lishui, Zhejiang, 323000, People’s Republic of China
1 shared publication
Latest Publications
- Open Access
- 1 December 2025
- Published by Taylor & Francis in Drug Design, Development and Therapy
- Vol. ume 19, 12077-12111
Therapeutic Targeting of Signaling Pathways in Abdominal Aortic Aneurysm: From Pathogenesis to Precision Medicine
Abdominal aortic aneurysms (AAAs) are life-threatening cardiovascular disorders with limited treatment options, largely due to an incomplete understanding of their molecular and cellular pathogenesis. A comprehensive elucidation of the mechanisms driving AAA initiation, progression, and rupture is critical for developing novel therapeutic interventions. Emerging research has highlighted the central role of inflammatory processes in AAA pathophysiology, including dysregulated extracellular matrix (ECM) remodeling, chronic vascular inflammation, immune cell infiltration, and vascular smooth muscle cell (VSMC) dysfunction. These pathological processes are regulated by complex signaling pathways with divergent roles in AAA progression: while NF-κB, MAPK, STAT, and Notch signaling exacerbate disease pathogenesis, AMPK, PPAR-γ, and Nrf2 pathways exert protective effects. Notably, the PI3K/Akt and TGF-β signaling cascades demonstrate context-dependent dual roles, capable of either promoting or inhibiting AAA development. This comprehensive review synthesizes current knowledge of AAA pathophysiology with emphasis on druggable targets within these signaling networks. We critically evaluate emerging therapeutic strategies including miRNA-based interventions, nanoparticle-mediated drug delivery systems, and stem cell therapies that offer promising approaches for precision modulation of disease-specific pathways. By integrating current mechanistic understanding with therapeutic development, this review aims to provide a framework for designing effective pharmacological strategies that could transform AAA management from surgical intervention to medical prevention, addressing a critical unmet clinical need.
- 1 December 2025
- Published by Taylor & Francis in Drug Design, Development and Therapy
- Vol. ume 19, 12077-12111
Open AccessTherapeutic Targeting of Signaling Pathways in Abdominal Aortic Aneurysm: From Pathogenesis to Precision Medicine
Abdominal aortic aneurysms (AAAs) are life-threatening cardiovascular disorders with limited treatment options, largely due to an incomplete understanding of their molecular and cellular pathogenesis. A comprehensive elucidation of the mechanisms driving AAA initiation, progression, and rupture is critical for developing novel therapeutic interventions. Emerging research has highlighted the central role of inflammatory processes in AAA pathophysiology, including dysregulated extracellular matrix (ECM) remodeling, chronic vascular inflammation, immune cell infiltration, and vascular smooth muscle cell (VSMC) dysfunction. These pathological processes are regulated by complex signaling pathways with divergent roles in AAA progression: while NF-κB, MAPK, STAT, and Notch signaling exacerbate disease pathogenesis, AMPK, PPAR-γ, and Nrf2 pathways exert protective effects. Notably, the PI3K/Akt and TGF-β signaling cascades demonstrate context-dependent dual roles, capable of either promoting or inhibiting AAA development. This comprehensive review synthesizes current knowledge of AAA pathophysiology with emphasis on druggable targets within these signaling networks. We critically evaluate emerging therapeutic strategies including miRNA-based interventions, nanoparticle-mediated drug delivery systems, and stem cell therapies that offer promising approaches for precision modulation of disease-specific pathways. By integrating current mechanistic understanding with therapeutic development, this review aims to provide a framework for designing effective pharmacological strategies that could transform AAA management from surgical intervention to medical prevention, addressing a critical unmet clinical need.
- Open Access
- 1 July 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 1-21
Targeting ESKAPE pathogens with ZnS and Au@ZnS Core–Shell nanoconjugates for improved biofilm control
The escalating prevalence of antibiotic-resistant infections and implant-related complications caused by biofilm-forming pathogens from the ESKAPE group, as identified by the World Health Organization (WHO), underscores the urgent need for innovative anti-biofilm strategies. Their occurrence on medical implants & prosthetic devices, as well as nosocomial infections in co-morbid patients, has become a global concern in the healthcare sector. In response, we investigated the efficacy of as-synthesized ZnS quantum dots (ZnS QD) and novel Au@ZnS nanoconjugates (Au@ZnS NC) against a spectrum of ESKAPE pathogens. The present study aimed to elucidate their antibacterial and anti-biofilm efficacy, focusing on Acinetobacter baumannii, Enterobacter cloacae, Staphylococcus epidermidis, Enterococcus faecium, Proteus mirabilis, Pseudomonas aeruginosa, Enterococcus faecalis, Staphylococcus aureus and Enterobacter aerogenes pathogens. The novel synthesis and application of ZnS QD and Au@ZnS core-shell NC demonstrate exceptional anti-biofilm efficacy, stability, and solubility in aqueous environments. Utilizing minimum inhibitory concentration (MIC) assays, tube dilution, and biofilm formation assay, we noticed a significant reduction in biofilm formation and extracellular polymeric substances (EPS) production upon treatment with Au@ZnS NC, even at low concentrations. Further investigations, including cell permeability assay, reactive oxygen species analysis, and comet analysis, demonstrated that the Au@ZnS NC induced oxidative stress, destabilizing cell structure, macromolecule destruction, and DNA strand breakage. Notably, Au@ZnS nanoconjugates effectively inhibited biofilm formation within 24 h across all tested strains, outperforming ZnS quantum dots. This research highlights the potential of Au@ZnS nanoconjugates to revolutionize infection control on medical devices and implants, offering a promising solution to the global healthcare challenge posed by biofilm-forming pathogens as we also observed minimal bacterial colonization on Au@ZnS treated urinary catheters.
- 1 July 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 1-21
Open AccessTargeting ESKAPE pathogens with ZnS and Au@ZnS Core–Shell nanoconjugates for improved biofilm control
The escalating prevalence of antibiotic-resistant infections and implant-related complications caused by biofilm-forming pathogens from the ESKAPE group, as identified by the World Health Organization (WHO), underscores the urgent need for innovative anti-biofilm strategies. Their occurrence on medical implants & prosthetic devices, as well as nosocomial infections in co-morbid patients, has become a global concern in the healthcare sector. In response, we investigated the efficacy of as-synthesized ZnS quantum dots (ZnS QD) and novel Au@ZnS nanoconjugates (Au@ZnS NC) against a spectrum of ESKAPE pathogens. The present study aimed to elucidate their antibacterial and anti-biofilm efficacy, focusing on Acinetobacter baumannii, Enterobacter cloacae, Staphylococcus epidermidis, Enterococcus faecium, Proteus mirabilis, Pseudomonas aeruginosa, Enterococcus faecalis, Staphylococcus aureus and Enterobacter aerogenes pathogens. The novel synthesis and application of ZnS QD and Au@ZnS core-shell NC demonstrate exceptional anti-biofilm efficacy, stability, and solubility in aqueous environments. Utilizing minimum inhibitory concentration (MIC) assays, tube dilution, and biofilm formation assay, we noticed a significant reduction in biofilm formation and extracellular polymeric substances (EPS) production upon treatment with Au@ZnS NC, even at low concentrations. Further investigations, including cell permeability assay, reactive oxygen species analysis, and comet analysis, demonstrated that the Au@ZnS NC induced oxidative stress, destabilizing cell structure, macromolecule destruction, and DNA strand breakage. Notably, Au@ZnS nanoconjugates effectively inhibited biofilm formation within 24 h across all tested strains, outperforming ZnS quantum dots. This research highlights the potential of Au@ZnS nanoconjugates to revolutionize infection control on medical devices and implants, offering a promising solution to the global healthcare challenge posed by biofilm-forming pathogens as we also observed minimal bacterial colonization on Au@ZnS treated urinary catheters.